Fmc- Wayne County is a medicare approved dialysis facility center in Monticello, Kentucky and it has 13 dialysis stations. It is located in Wayne county at 40 Walmart Plaza Drive, Monticello, KY, 42633. You can reach out to the office of Fmc- Wayne County at (606) 348-3895. This dialysis clinic is managed and/or owned by Fresenius Medical Care. Fmc- Wayne County has the following ownership type - Profit. It was first certified by medicare in February, 2017. The medicare id for this facility is 182634 and it accepts patients under medicare ESRD program.
| Name | Fmc- Wayne County |
|---|---|
| Location | 40 Walmart Plaza Drive, Monticello, Kentucky |
| No. of Dialysis Stations | 13 |
| Medicare ID | 182634 |
| Managed By | Fresenius Medical Care |
| Ownership Type | Profit |
| Late Shifts | No |
| 40 Walmart Plaza Drive, Monticello, Kentucky, 42633 | |
| (606) 348-3895 | |
| Not Available |
News Archive
Case Western Reserve researchers have identified a genetic factor that blocks the blood vessel inflammation that can lead to heart attacks, strokes and other potentially life-threatening events.
Research at Umeå University provides new insights into when during the menstrual cycle it is advantageous to periodise your strength training.
Women who have had severe cell changes in the cervix and who have been operated on for them run twice the risk of developing cancer later in life, compared with other women.
Argos Therapeutics, Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on the Arcelis technology platform, today announced that the NIH Division of AIDS (DAIDS) has approved $6.6 million in funding for an investigator-initiated Phase 2a adult eradication study of AGS-004, the company's investigational fully personalized immunotherapy for HIV.
› Verified 9 days ago
| NPI Number | 1770939241 |
| Organization Name | Fresenius Kidney Care Wayne County |
| Doing Business As | Bio-medical Applications Of Kentucky, Inc. |
| Address | 40 Walmart Plaza Dr Monticello, Kentucky, 42633 |
| Phone Number | (606) 348-3895 |
News Archive
Case Western Reserve researchers have identified a genetic factor that blocks the blood vessel inflammation that can lead to heart attacks, strokes and other potentially life-threatening events.
Research at Umeå University provides new insights into when during the menstrual cycle it is advantageous to periodise your strength training.
Women who have had severe cell changes in the cervix and who have been operated on for them run twice the risk of developing cancer later in life, compared with other women.
Argos Therapeutics, Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on the Arcelis technology platform, today announced that the NIH Division of AIDS (DAIDS) has approved $6.6 million in funding for an investigator-initiated Phase 2a adult eradication study of AGS-004, the company's investigational fully personalized immunotherapy for HIV.
› Verified 9 days ago
| Dialysis patients with Hemoglobin data | 5 |
News Archive
Case Western Reserve researchers have identified a genetic factor that blocks the blood vessel inflammation that can lead to heart attacks, strokes and other potentially life-threatening events.
Research at Umeå University provides new insights into when during the menstrual cycle it is advantageous to periodise your strength training.
Women who have had severe cell changes in the cervix and who have been operated on for them run twice the risk of developing cancer later in life, compared with other women.
Argos Therapeutics, Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on the Arcelis technology platform, today announced that the NIH Division of AIDS (DAIDS) has approved $6.6 million in funding for an investigator-initiated Phase 2a adult eradication study of AGS-004, the company's investigational fully personalized immunotherapy for HIV.
› Verified 9 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 21 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 83 |
| Percentage of adult patients getting regular hemodialysis at the center | 99 |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
Case Western Reserve researchers have identified a genetic factor that blocks the blood vessel inflammation that can lead to heart attacks, strokes and other potentially life-threatening events.
Research at Umeå University provides new insights into when during the menstrual cycle it is advantageous to periodise your strength training.
Women who have had severe cell changes in the cervix and who have been operated on for them run twice the risk of developing cancer later in life, compared with other women.
Argos Therapeutics, Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on the Arcelis technology platform, today announced that the NIH Division of AIDS (DAIDS) has approved $6.6 million in funding for an investigator-initiated Phase 2a adult eradication study of AGS-004, the company's investigational fully personalized immunotherapy for HIV.
› Verified 9 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Fmc- Wayne County with elevated calcium levels.
| Patients with hypercalcemia | 22 |
| Hypercalcemia patient months | 87 |
| Patients with Serumphosphor | 22 |
| Patients with Serumphosphor less than 3.5 mg/dL | 8 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 22 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 46 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 15 |
| Patients with Serumphosphor greater than 7 mg/dL | 9 |
News Archive
Case Western Reserve researchers have identified a genetic factor that blocks the blood vessel inflammation that can lead to heart attacks, strokes and other potentially life-threatening events.
Research at Umeå University provides new insights into when during the menstrual cycle it is advantageous to periodise your strength training.
Women who have had severe cell changes in the cervix and who have been operated on for them run twice the risk of developing cancer later in life, compared with other women.
Argos Therapeutics, Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on the Arcelis technology platform, today announced that the NIH Division of AIDS (DAIDS) has approved $6.6 million in funding for an investigator-initiated Phase 2a adult eradication study of AGS-004, the company's investigational fully personalized immunotherapy for HIV.
› Verified 9 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 23 |
| Patient months included in arterial venous fistula and catheter summaries | 95 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 72 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 8 |
News Archive
Case Western Reserve researchers have identified a genetic factor that blocks the blood vessel inflammation that can lead to heart attacks, strokes and other potentially life-threatening events.
Research at Umeå University provides new insights into when during the menstrual cycle it is advantageous to periodise your strength training.
Women who have had severe cell changes in the cervix and who have been operated on for them run twice the risk of developing cancer later in life, compared with other women.
Argos Therapeutics, Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on the Arcelis technology platform, today announced that the NIH Division of AIDS (DAIDS) has approved $6.6 million in funding for an investigator-initiated Phase 2a adult eradication study of AGS-004, the company's investigational fully personalized immunotherapy for HIV.
› Verified 9 days ago